PlainRecalls
FDA Devices Moderate Class II Terminated

T12. Incorporates wireless electrocardiographic technology to achieve the real-time acquisition and RF transmission of simultaneous 12-lead ECG data with diagnostic quality while allowing the patient to be ambulatory.

Reported: May 6, 2020 Initiated: March 18, 2020 #Z-1813-2020

Product Description

T12. Incorporates wireless electrocardiographic technology to achieve the real-time acquisition and RF transmission of simultaneous 12-lead ECG data with diagnostic quality while allowing the patient to be ambulatory.

Reason for Recall

Impacted Welch Allyn products may not meet the Defibrillation Withstand requirements of EN/IEC 60601-2-25 Medical Electrical Equipment.

Details

Recalling Firm
WELCH ALLYN, INC/MORTARA
Units Affected
78,521 units total
Distribution
US nationwide distribution in the states of AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, ON, OR, PA, PR, RI, SC, SD, TN,UT, VA, VT, WA, WI, WV and WY.
Location
Milwaukee, WI

Frequently Asked Questions

What product was recalled?
T12. Incorporates wireless electrocardiographic technology to achieve the real-time acquisition and RF transmission of simultaneous 12-lead ECG data with diagnostic quality while allowing the patient to be ambulatory.. Recalled by WELCH ALLYN, INC/MORTARA. Units affected: 78,521 units total.
Why was this product recalled?
Impacted Welch Allyn products may not meet the Defibrillation Withstand requirements of EN/IEC 60601-2-25 Medical Electrical Equipment.
Which agency issued this recall?
This recall was issued by the FDA Devices on May 6, 2020. Severity: Moderate. Recall number: Z-1813-2020.